CPHI Korea is Korea's leading B2B exhibition connecting supply chains and businesses in the pharmaceutical, biotechnology, and healthcare industries.
The 2026 event will be held at COEX in Seoul from August 25 to 27, bringing together active pharmaceutical ingredient (API) manufacturers, biotech companies, CDMO/OEM providers, pharmaceutical equipment manufacturers, nutraceutical and functional food enterprises, as well as domestic and international buyers and decision-makers.

Key Highlights:

• Attendees from 80+ countries and regions

• 420+ exhibiting companies

• 12,000+ visitors

• Core sectors including APIs, biopharmaceuticals, CDMO, pharmaceutical equipment, and nutraceuticals/functional foods

Booth Location
C15

NeoCremar has initiated a preclinical study to validate the veterinary functional efficacy of its galacto-oligosaccharide ingredient, NeoGOS-P70.
This study, scheduled to run for approximately six months, will evaluate the potential of NeoGOS-P70 to improve gut health and skin barrier function in healthy companion dogs. The research will be conducted by Limpid Inc., a specialized veterinary clinical research organization, and will ensure scientific credibility through research advisory from the College of Veterinary Medicine at Seoul National University.
Through this study, NeoCremar aims to verify the potential application of NeoGOS-P70 in the companion animal sector and secure foundational data for future business expansion into the pet food and supplement markets. Furthermore, the company plans to pursue publication in international peer-reviewed journals based on the study findings.
We will continue to secure scientific evidence for our functional ingredients and expand the applicability of NeoGOS-P70 across diverse sectors.

NeoCremar has been selected as a joint research institution and has completed the agreement for the 'Development and Commercialization of Digestive Health Care Food Ingredients' project, a leading R&D initiative under the 'Regional Innovation Cluster Fosterage (R&D) Program' supported by the Ministry of Trade, Industry and Energy.
This project is led by Hamsoa Pharmaceutical Co., Ltd., with NeoCremar and the Korea Food Research Institute (KFRI) participating as joint research institutions, and will be conducted from 2026 to 2030. The project aims to develop functional ingredients to promote digestive health using AI technology, organoids, and multi-omics technologies, and to establish a foundation for the commercialization of health functional foods and care foods.
Through this project, NeoCremar plans to strengthen its research capabilities in functional ingredients, contribute to the development of next-generation functional ingredients in the digestive health sector, and commercialize individually approved health functional foods. Furthermore, based on industry-academia-research collaboration, we intend to enhance our competitiveness in domestic and global markets and secure new growth opportunities.
We will continue to do our best to strengthen our competitiveness in the functional ingredients sector and enhance corporate value through continuous research and development and technological innovation.